Tags

Type your tag names separated by a space and hit enter

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.
Neurology 2005; 64(9):1531-8Neur

Abstract

OBJECTIVE

To examine the association of plasma cholesterol levels, lipid-lowering agent (LLA) intake, and APOE genotype with dementia prevalence.

METHODS

The Three-City Study is a population-based cohort of 9,294 subjects selected from the electoral rolls of three French cities (Bordeaux, Dijon, Montpellier). Baseline examination included extensive assessment of exposure to vascular risk factors (including cholesterol levels and LLA use [statin or fibrate]) and clinical diagnosis of dementia.

RESULTS

Two percent of participants were demented at baseline. Overall 32.4% of participants had hyperlipidemia, and 15.6% were prescribed statins and 13.7% fibrates. After adjusting for age, gender, education level, and study center, the odds ratio (OR) for dementia was observed to be lower among LLA users (OR = 0.61, 95% CI = 0.41 to 0.91) compared with subjects taking no LLAs. There was no differential effect between statin and fibrate users. The odds for dementia were increased in subjects with hyperlipidemia (OR = 1.43, 95% CI = 1.03 to 1.99). Further adjustment for potential confounders did not modify these associations. In addition, the association between LLA intake and dementia was not modified by APOE genotype, whereas hyperlipidemia was significantly associated with increased dementia prevalence only in non-epsilon4 carriers and non-Alzheimer disease cases. Finally, in participants taking LLAs, the odds for dementia were decreased only in those having normal lipid levels.

CONCLUSIONS

This observational study provides further evidence that lipid-lowering agents are associated with decreased risk of dementia, whereas hyperlipidemia is associated with increased odds for non-Alzheimer-disease-type dementia. These effects appear to be independent of all major potential confounders.

Authors+Show Affiliations

Institut National de la Santé et de la Recherche Médicale U360, Hopital La Salpêtrière, Paris, France. carole.dufouil@chups.jussieu.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15883313

Citation

Dufouil, C, et al. "APOE Genotype, Cholesterol Level, Lipid-lowering Treatment, and Dementia: the Three-City Study." Neurology, vol. 64, no. 9, 2005, pp. 1531-8.
Dufouil C, Richard F, Fiévet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology. 2005;64(9):1531-8.
Dufouil, C., Richard, F., Fiévet, N., Dartigues, J. F., Ritchie, K., Tzourio, C., ... Alpérovitch, A. (2005). APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology, 64(9), pp. 1531-8.
Dufouil C, et al. APOE Genotype, Cholesterol Level, Lipid-lowering Treatment, and Dementia: the Three-City Study. Neurology. 2005 May 10;64(9):1531-8. PubMed PMID: 15883313.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. AU - Dufouil,C, AU - Richard,F, AU - Fiévet,N, AU - Dartigues,J F, AU - Ritchie,K, AU - Tzourio,C, AU - Amouyel,P, AU - Alpérovitch,A, PY - 2005/5/11/pubmed PY - 2006/1/7/medline PY - 2005/5/11/entrez SP - 1531 EP - 8 JF - Neurology JO - Neurology VL - 64 IS - 9 N2 - OBJECTIVE: To examine the association of plasma cholesterol levels, lipid-lowering agent (LLA) intake, and APOE genotype with dementia prevalence. METHODS: The Three-City Study is a population-based cohort of 9,294 subjects selected from the electoral rolls of three French cities (Bordeaux, Dijon, Montpellier). Baseline examination included extensive assessment of exposure to vascular risk factors (including cholesterol levels and LLA use [statin or fibrate]) and clinical diagnosis of dementia. RESULTS: Two percent of participants were demented at baseline. Overall 32.4% of participants had hyperlipidemia, and 15.6% were prescribed statins and 13.7% fibrates. After adjusting for age, gender, education level, and study center, the odds ratio (OR) for dementia was observed to be lower among LLA users (OR = 0.61, 95% CI = 0.41 to 0.91) compared with subjects taking no LLAs. There was no differential effect between statin and fibrate users. The odds for dementia were increased in subjects with hyperlipidemia (OR = 1.43, 95% CI = 1.03 to 1.99). Further adjustment for potential confounders did not modify these associations. In addition, the association between LLA intake and dementia was not modified by APOE genotype, whereas hyperlipidemia was significantly associated with increased dementia prevalence only in non-epsilon4 carriers and non-Alzheimer disease cases. Finally, in participants taking LLAs, the odds for dementia were decreased only in those having normal lipid levels. CONCLUSIONS: This observational study provides further evidence that lipid-lowering agents are associated with decreased risk of dementia, whereas hyperlipidemia is associated with increased odds for non-Alzheimer-disease-type dementia. These effects appear to be independent of all major potential confounders. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/15883313/APOE_genotype_cholesterol_level_lipid_lowering_treatment_and_dementia:_the_Three_City_Study_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=15883313 DB - PRIME DP - Unbound Medicine ER -